Type 2 Diabetes

A considerable amount of progress has been made in treating diabetes this year both for type 1 and type 2 diabetes. The approval of new medications and potential devices in the future have made for a bright outlook for patients.

Dietary trans fatty acids have had their heyday and are fading from the American food landscape. Once ubiquitous in margarine, snack food, packaged baked goods, and fried fast food, they have been associated with adverse effects on lipid profiles, metabolic function, insulin resistance, inflammation, and cardiac and general health.

In previous studies, regular breakfast consumption has been correlated with lower BMI and improved cardiometabolic risk profile. Furthermore, evidence suggests that low-energy density, high-fiber, and high-carbohydrate foods may be more satiating when compared to their alternatives.

Although some studies have hinted at a possible role for metformin in pain management, a recent investigation found no difference in pain scores among diabetic patients who used metformin and those who did not

Exercise is one of the mainstays of diabetes treatment. Recent research shows that the higher the level of fitness, the lower the risk of an individual developing diabetes.

Researchers study whether or not GLP-1 affects pancreatic amylase or lipase plasma concentrations.

GLP-1 inhibition may have an anti-atherogenic action that involves both glucose and lipid metabolism.

Epidemiological studies have provided conflicting evidence regarding the impact of dietary cholesterol and egg consumption on heart disease risk in patients with type 2 diabetes mellitus (T2DM). Also controversial is the idea that dietary cholesterol may contribute to the very development of T2DM by altering glucose metabolism. Given the significant influence of diet on diabetes management, the lack of conclusive evidence on this subject emphasizes the need for further study.

The Paleolithic (grain-free) diet is gathering steam among dieters and health conscious individuals alike. Proponents consume only items that, hypothetically, cavemen would have had access to. They claim that modern man can't metabolize comparatively new types of food, and our reliance on processed foods has increased rates of obesity, heart disease, and diabetes.

Test your knowledge of recent findings in SGLT2 inhibitor efficacy and safety research.

It can be difficult to determine which combinations of antihyperglycemic medications might work best, and for which patients. A recent review investigates combined therapy, with a focus on the newer DPP-4 and SGLT2 inhibitors.

We highlight 3 recent studies concerning pregnancy and diabetes and ways to potentially reduce health risks of both mother and child.

Our blogger shares her hope that the potentially life-saving continuous glucose sensors will soon be covered by all health plans.

Diabetic kidney disease does not have the telltale signs of other conditions which can make it difficult to spot. However, with the right tests patients can get the treatments they need.

Diabetic kidney disease does not have the telltale signs of other conditions which can make it difficult to spot. However, with the right tests patients can get the treatments they need.

One of the newest developments in the treatment of diabetes is the GLP-1 receptor agonist. With different forms intended for different populations it continues a longstanding pattern of bringing new medications into the pool of options for doctors to choose from.

There is no shortage of medications for type 2 diabetes but as the number of patients also increases work is underway to find the best options for everyone with the condition.

What's your approach to treating patients? Weigh in on what you stand for when it comes to health care.

A recent study of a medication used to help patients with angina could also help those with diabetes. How much of a benefit it can provide remains to be determined.

With new medications and therapies being developed for a variety of conditions, a consistent message from the medical community can help move treatment forward.

Results from the TECOS trial indicate patients with type 2 diabetes and cardiovascular disease treated with sitagliptin are not at higher risk for cardiovascular events or hospitalization.

There can be significant obstacles for healthcare professionals in the United States treating Hispanic and Latino patients, particularly when a language barrier is involved.

A recent study looked at whether metabolic syndrome confers a greater cancer risk than the sum of its individual components and component associations, and whether it is a useful predictor for future cancer risk.

Diabetes is an ever growing problem in the latino community which also continues to grow in the United States. Addressing the condition in these patients is sometimes about more than just knowing the medications they require.

Although patients with diabetes who were at high risk for cardiovascular events did not benefit from treatment with lixisenatide, results from the ELIXA study showed that the drug is safe in this population.

Study results show combination treatment with empagliflozin and linagliptin effectively reduced HbA1c in patients with type 2 diabetes mellitus.

Obesity contributes to significant morbidity and mortality among primary care patients. This paper summarizes options for pharmacological management of obesity. Medications approved for obesity are Phenteremine/Topiramate, Orlistat, Lorcaserin, Naltrexone/Bupropion, Liraglutide.

As the diabetes epidemic continues to grow doctors are being faced with the task of stopping or reversing the trend.

For patients with diabetes controlling their condition is largely in their hands. How they work the process can determine their overall quality of life.

Alogliptin appears to slow the progression of carotid atherosclerosis in patients with type 2 diabetes mellitus.